TSBX — Turnstone Biologics Cashflow Statement
0.000.00%
Last trade - 00:00- $8.10m
- -$20.83m
Annual cashflow statement for Turnstone Biologics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | 33.3 | -30.8 | -55.2 | -70.8 |
| Depreciation | ||||
| Deferred Taxes | ||||
| Non-Cash Items | 5.47 | 13.8 | 4.17 | 1.52 |
| Unusual Items | ||||
| Other Non-Cash Items | ||||
| Changes in Working Capital | -85.7 | -58 | -17.9 | 0.047 |
| Change in Accounts Receivable | ||||
| Change in Prepaid Expenses | ||||
| Change in Other Assets | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Other Liabilities | ||||
| Cash from Operating Activities | -45.6 | -71.1 | -66.2 | -67.4 |
| Capital Expenditures | -3.41 | -5.17 | -1.25 | -0.229 |
| Purchase of Fixed Assets | ||||
| Other Investing Cash Flow Items | 0.058 | -9.76 | -26.8 | 78.8 |
| Sale of Fixed Assets | ||||
| Sale/Maturity of Investment | ||||
| Purchase of Investments | ||||
| Cash from Investing Activities | -3.35 | -14.9 | -28.1 | 78.6 |
| Financing Cash Flow Items | — | -2.81 | -0.898 | -0.033 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Stock | ||||
| Cash from Financing Activities | 80 | -2.66 | 77 | 0.011 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 31 | -88.7 | -17.2 | 11.1 |